Oscient To Market Antara Using 280-Person Primary Care Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
Oscient acquired the U.S. rights to the fenofibrate drug from Reliant for $78 mil.
You may also be interested in...
Reliant Submits Response To FDA For Expanded Omacor Indication
Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.
Reliant Submits Response To FDA For Expanded Omacor Indication
Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.
Reliant Launches Omacor With Existing Sales Force
Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.